|
1
|
Agarwal N, Pal SK, Hahn AW, Nussenzveig
RH, Pond GR, Gupta SV, Wang J, Bilen MA, Naik G, Ghatalia P, et al:
Characterization of metastatic urothelial carcinoma via
comprehensive genomic profiling of circulating tumor DNA. Cancer.
124:2115–2124. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Antoni S, Ferlay J, Soerjomataram I, Znaor
A, Jemal A and Bray F: Bladder cancer incidence and mortality: A
global overview and recent trends. Eur Urol. 71:96–108. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Amin MB, Smith SC, Reuter VE, Epstein JI,
Grignon DJ, Hansel DE, Lin O, McKenney JK, Montironi R, Paner GP,
et al: Update for the practicing pathologist: The international
consultation on urologic disease-European association of urology
consultation on bladder cancer. Mod Pathol. 28:612–630. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kang M, Jeong CW, Kwak C, Kim HH and Ku
JH: Preoperative neutrophil-lymphocyte ratio can significantly
predict mortality outcomes in patients with non-muscle invasive
bladder cancer undergoing transurethral resection of bladder tumor.
Oncotarget. 8:12891–12901. 2017.PubMed/NCBI
|
|
5
|
Liang B, He X, Shang D, Tian Y and Liu Z:
The link between FOXJ1 expression level in bladder carcinoma and
tumor recurrence. Oncol Lett. 15:1483–1486. 2018.PubMed/NCBI
|
|
6
|
Soria F, Gurioli A, Peraldo F, Oderda M,
Giona S, Ambrosini E, Frea B and Gontero P: Innovations in the
endoscopic management of bladder cancer: Is the era of white light
cystoscopy over. Urologia. 80:1–8. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schmitz-Dräger BJ, Droller M, Lokeshwar
VB, Lotan Y, Hudson MA, van Rhijn BW, Marberger MJ, Fradet Y,
Hemstreet GP, Malmstrom PU, et al: Molecular markers for bladder
cancer screening, early diagnosis, and surveillance: The WHO/ICUD
consensus. Urol Int. 94:1–24. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mowatt G, Zhu S, Kilonzo M, Boachie C,
Fraser C, Griffiths TR, N'Dow J, Nabi G, Cook J and Vale L:
Systematic review of the clinical effectiveness and
cost-effectiveness of photodynamic diagnosis and urine biomarkers
(FISH, ImmunoCyt, NMP22) and cytology for the detection and
follow-up of bladder cancer. Health Technol Assess. 14(1–331):
iii–iv. 2010.
|
|
9
|
Lotan Y and Roehrborn CG: Sensitivity and
specificity of commonly available bladder tumor markers versus
cytology: Results of a comprehensive literature review and
meta-analyses. Urology. 61:109–118. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schwalb DM, Herr HW and Fair WR: The
management of clinically unconfirmed positive urinary cytology. J
Urol. 150:1751–1756. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kamat AM, Hahn NM, Efstathiou JA, Lerner
SP, Malmström PU, Choi W, Lotan Y and Kassouf W: Bladder cancer.
388:2796–2810. 2016.
|
|
12
|
Dawam D: Biomarkers of bladder cancer in
urine: Evaluation of diagnostic and prognostic significance of
current and potential markersBladder Cancer-From Basic Science to
Robotic Surgery. Abdullah Canda: InTech Europe; Rijeka: 2012,
https://www.intechopen.com/books/bladder-cancer-from-basic-science-to-robotic-surgery/biomarkers-of-bladder-cancer-in-urine-evaluation-of-diagnostic-and-prognostic-significance-of-currenFebruary
1–2012 View
Article : Google Scholar
|
|
13
|
Witjes JA, Compérat E, Cowan NC, De Santis
M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG and Sherif A:
European Association of Urology: EAU guidelines on muscle-invasive
and metastatic bladder cancer: Summary of the 2013 guidelines. Eur
Urol. 65:778–792. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ritter R, Hennenlotter J, Kühs U, Hofmann
U, Aufderklamm S, Blutbacher P, Deja A, Hohneder A, Gerber V, Gakis
G, et al: Evaluation of a new quantitative point-of-care test
platform for urine-based detection of bladder cancer. Urol Oncol.
32:337–344. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ecke TH, Arndt C, Stephan C, Hallmann S,
Lux O, Otto T, Ruttloff J and Gerullis H: Preliminary results of a
multicentre study of the UBC rapid test for detection of urinary
bladder cancer. Anticancer Res. 35:2651–2655. 2015.PubMed/NCBI
|
|
16
|
Styrke J, Henriksson H, Ljungberg B, Hasan
M, Silfverberg I, Einarsson R, Malmström PU and Sherif A:
Evaluation of the diagnostic accuracy of UBC® Rapid in
bladder cancer: A Swedish multicentre study. Scand J Urol.
51:293–300. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Barak V, Goike H, Panaretakis KW and
Einarsson R: Clinical utility of cytokeratins as tumor markers.
Clin Biochem. 37:529–540. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sumi S, Arai K, Kitahara S and Yoshida KI:
Preliminary report of the clinical performance of a new urinary
bladder cancer antigen test: Comparison to voided urine cytology in
the detection of transitional cell carcinoma of the bladder. Clin
Chim Acta. 296:111–120. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Giannopoulos A, Manousakas T, Gounari A,
Constantinides C, Choremi-Papadopoulou H and Dimopoulos C:
Comparative evaluation of the diagnostic performance of the BTA
stat test, NMP22 and urinary bladder cancer antigen for primary and
recurrent bladder tumors. J Urol. 166:470–475. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gleichenhagen J, Arndt C, Casjens S,
Meinig C, Gerullis H, Raiko I, Brüning T, Ecke T and Johnen G:
Evaluation of a new survivin ELISA and UBC® Rapid for the detection
of bladder cancer in urine. Int J Mol Sci. 19:pii: E226. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pichler R, Tulchiner G, Fritz J, Schaefer
G, Horninger W and Heidegger I: Urinary UBC rapid and NMP22 test
for bladder cancer surveillance in comparison to urinary cytology:
results from a prospective single-center study. Int J Med Sci.
14:811–819. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ecke TH, Weiß S, Stephan C, Hallmann S,
Barski D, Otto T and Gerullis H: UBC® Rapid test for detection of
carcinoma in situ for bladder cancer. Tumour Biol.
39:10104283177016242017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schueler S, Schuetz GM and Dewey M: The
revised QUADAS-2 tool. Ann Intern Med. 156:323–324. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rosenblat MA, Perrotta AS and Vicenzino B:
Polarized vs. threshold training intensity distribution on
endurance sport performance: A systematic review and meta-analysis
of randomized controlled trials. J Strength Cond Res. May
30–2018.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hajian-Tilaki K: Receiver operating
characteristic (ROC) curve analysis for medical diagnostic test
evaluation. Caspian J Intern Med. 4:627–635. 2013.PubMed/NCBI
|
|
26
|
Bae JM: An overview of systematic reviews
of diagnostic tests accuracy. Epidemiol Health. 36:e20140162014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gopalakrishna G, Langendam MW, Scholten
RJ, Bossuyt PM and Leeflang MM: Defining the clinical pathway in
cochrane diagnostic test accuracy reviews. BMC Med Res Methodol.
16:1532016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
van Enst WA, Ochodo E, Scholten RJ, Hooft
L and Leeflang MM: Investigation of publication bias in
meta-analyses of diagnostic test accuracy: A meta-epidemiological
study. BMC Med Res Methodol. 14:702014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zamora J, Abraira V, Muriel A, Khan K and
Coomarasamy A: Meta-DiSc: A software for meta-analysis of test
accuracy data. BMC Med Res Methodol. 6:312006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Deeks JJ, Macaskill P and Irwig L: The
performance of tests of publication bias and other sample size
effects in systematic reviews of diagnostic test accuracy was
assessed. J Clin Epidemiol. 58:882–893. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mian C, Lodde M, Haitel A, Vigl Egarter E,
Marberger M and Pycha A: Comparison of two qualitative assays, the
UBC rapid test and the BTA stat test, in the diagnosis of
urothelial cell carcinoma of the bladder. Urology. 56:228–231.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Babjuk M, Kostírová M, Mudra K, Pecher S,
Smolová H, Pecen L, Ibrahim Z, Dvorácek J, Jarolím L, Novák J and
Zima T: Qualitative and quantitative detection of urinary human
complement factor H-related protein (BTA stat and BTA TRAK) and
fragments of cytokeratins 8, 18 (UBC rapid and UBC IRMA) as markers
for transitional cell carcinoma of the bladder. Eur Urol. 41:34–39.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Schroeder GL, Lorenzo-Gomez MF, Hautmann
SH, Friedrich MG, Ekici S, Huland H and Lokeshwar V: A side by side
comparison of cytology and biomarkers for bladder cancer detection.
J Urol. 172:1123–1136. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hakenberg OW, Fuessel S, Richter K,
Froehner M, Oehlschlaeger S, Rathert P, Meye A and Wirth MP:
Qualitative and quantitative assessment of urinary cytokeratin 8
and 18 fragments compared with voided urine cytology in diagnosis
of bladder carcinom. Urology. 64:1121–1126. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Feber A, Dhami P, Dong L, de Winter P, Tan
WS, Martínez-Fernández M, Paul DS, Hynes-Allen A, Rezaee S, Gurung
P, et al: UroMark-a urinary biomarker assay for the detection of
bladder cancer. Clin Epigenetics. 9:82017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Burger M, Grossman HB, Droller M,
Schmidbauer J, Hermann G, Drăgoescu O, Ray E, Fradet Y, Karl A,
Burgués JP, et al: Photodynamic diagnosis of non-muscle-invasive
bladder cancer with hexaminolevulinate cystoscopy: A meta-analysis
of detection and recurrence based on raw data. Eur Urol.
64:846–854. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xylinas E, Kluth LA, Rieken M, Karakiewicz
PI, Lotan Y and Shariat SF: Urine markers for detection and
surveillance of bladder cancer. Urol Oncol. 32:222–229. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Glas AS, Lijmer JG, Prins MH, Bonsel GJ
and Bossuyt PM: The diagnostic odds ratio: A single indicator of
test performance. J Clin Epidemiol. 56:1129–1135. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sedighi I: Interpretation of diagnostic
tests: Likelihood ratio vs. Predictive value. Iran J Pediatr.
23:7172013.PubMed/NCBI
|
|
40
|
Liberati A, Altman DG, Tetzlaff J, Mulrow
C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J
and Moher D: The PRISMA statement for reporting systematic reviews
and meta-analyses of studies that evaluate healthcare
interventions: Explanation and elaboration. BMJ. 339:b27002009.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rubia K, Alegria AA, Cubillo AI, Smith AB,
Brammer MJ and Radua J: Effects of stimulants on brain function in
attention-deficit/hyperactivity disorder: A systematic review and
meta-analysis. Biol Psychiatry. 76:616–628. 2014. View Article : Google Scholar : PubMed/NCBI
|
